Aripiprazole Completed Phase 2 / 3 Trials for Schizophrenia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT03557931A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
NCT00509067Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
NCT00202007Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
NCT00580125Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
NCT00845026A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
NCT00905307Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia